000			01744 a2200493 4500
005			20250515201858.0
264		0	_c20100427
008			201004s 0 0 eng d
022			_a1179-1950
024	7		_a10.2165/11203820-000000000-00000 _2doi
040			_aNLM _beng _cNLM
100	1		_aCarter, Natalie J
245	0	0	_aBesifloxacin ophthalmic suspension 0.6%. _h[electronic resource]
260			_bDrugs _c2010
300			_a83-97 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdministration, Topical
650	0	4	_aAnti-Bacterial Agents _xpharmacology
650	0	4	_aAntifungal Agents _xpharmacology
650	0	4	_aAza Compounds _xpharmacology
650	0	4	_aAzepines _xtherapeutic use
650	0	4	_aColony Count, Microbial
650	0	4	_aConjunctivitis, Bacterial _xdrug therapy
650	0	4	_aDNA Gyrase _xmetabolism
650	0	4	_aDNA Topoisomerase IV _xmetabolism
650	0	4	_aDouble-Blind Method
650	0	4	_aDrug Administration Schedule
650	0	4	_aEye
650	0	4	_aFluoroquinolones _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aMethicillin Resistance
650	0	4	_aMethicillin-Resistant Staphylococcus aureus
650	0	4	_aMicrobial Sensitivity Tests
650	0	4	_aMoxifloxacin
650	0	4	_aOphthalmic Solutions _xtherapeutic use
650	0	4	_aQuinolines _xpharmacology
650	0	4	_aStaphylococcal Infections _xdrug therapy
650	0	4	_aStaphylococcus aureus _xdrug effects
650	0	4	_aStreptococcus pneumoniae _xdrug effects
650	0	4	_aSuspensions _xtherapeutic use
700	1		_aScott, Lesley J
773	0		_tDrugs _gvol. 70 _gno. 1 _gp. 83-97
856	4	0	_uhttps://doi.org/10.2165/11203820-000000000-00000 _zAvailable from publisher's website
999			_c19410878 _d19410878